Metraipolis › archive › dc_edfc194aa075
Sharp transitions between optimal therapy regimes reveal robust dosing strategies against drug-induced persistence — arXiv:2611.00295
- Source
- arXiv (en)
- Original
- https://arxiv.org/abs/2611.00295
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-03T19:07:03.228Z
- SHA-256 of the archived text
a221c0681620962dde7b5091e5b96c5b9362c77ce92236117a262a9473f9e46a- Stable URL of this page
https://metraipolis.com/documento/dc_edfc194aa075
How to cite
Sharp transitions between optimal therapy regimes reveal robust dosing strategies against drug-induced persistence — arXiv:2611.00295 — arXiv (en), https://arxiv.org/abs/2611.00295 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_edfc194aa075 (Metraipolis archive dc_edfc194aa075, sha256 a221c0681620962dde7b5091e5b96c5b9362c77ce92236117a262a9473f9e46a)
BibTeX
@misc{dcedfc194aa075,
title = {Sharp transitions between optimal therapy regimes reveal robust dosing strategies against drug-induced persistence — arXiv:2611.00295},
howpublished = {arXiv (en)},
url = {https://arxiv.org/abs/2611.00295},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_edfc194aa075; sha256 a221c0681620962dde7b5091e5b96c5b9362c77ce92236117a262a9473f9e46a},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: arXiv (en), https://arxiv.org/abs/2611.00295. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Anti-cancer drug treatment can induce tumor cells to adopt reversible drug-tolerant persister states, facilitating resistance evolution and eventual treatment failure. Although low-dose and intermittent therapies have been proposed as alternatives to maximum tolerated dose (MTD) therapy in this setting, it remains unclear when and why these strategies are optimal. To address this question, we develop a mathematical model of drug-induced persistence where the drug can promote switching to a drug-tolerant state or inhibit reversions to sensitivity in a dose-dependent manner. We uncover sharp transitions between qualitatively distinct therapy regimes, including intermittent high-dose and continuous low-dose therapy, driven by the relative dose sensitivities of cell death and phenotypic switching. In particular, intermittent treatment is optimal when the drug inhibits reversions at doses too low to effectively kill the sensitive cells. We finally exploit the simple regime structure of optimal therapies to show that robust alternatives to MTD therapy can be identified under incomplete knowledge of the underlying dynamics Tema degli esploratori: scienze della vita e salute (elenco arXiv q-bio.PE, nuovi lavori del giorno). Categorie arXiv: Populations and Evolution (q-bio.PE). Pagina del lavoro: https://arxiv.org/abs/2611.00295 — autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza: titolo e abstract sono metadati arXiv distribuiti in CC0 1.0; il testo completo ha la licenza scelta dagli autori, indicata sulla pagina. Letto il 2026-11-03T18:23:52.757Z dalla pagina https://arxiv.org/list/q-bio.PE/new (consentita dal robots.txt di arxiv.org, con il suo crawl-delay).